Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603432 · ClinicalTrials.gov registry record · Phase 3
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
A Phase 3 study of Urothelial Cancer, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT02603432: Completed Phase 3 study of Urothelial Cancer, sponsored by Pfizer.
NCT02603432 is a Phase 3 study of Urothelial Cancer that has completed, run by Pfizer. The registered enrollment target is 700 participants, above the 546-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02603432, a Phase 3 study of Urothelial Cancer, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.
Primary Outcome
Overall survival was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.
Conditions Studied
Interventions
- BIOLOGICAL Avelumab
- OTHER Best Supportive Care
- BIOLOGICAL Following the planned interim analysis for this study: Avelumab
Study Locations (20)
Colorado
- Anschutz Cancer Center Pavilion Pharmacy - Aurora
- University of Colorado Cancer Center - Aurora
- University of Colorado Denver, CTO (CTRC) - Aurora
- University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) - Aurora
- University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) - Aurora
Ohio
- Cleveland Clinic Taussing Cancer Center - Cleveland
- Cleveland Clinic Taussing Cancer Center - Cleveland
- Cleveland Clinic Foundation - Cleveland
- Cleveland Clinic Taussing Cancer Center - Cleveland
Washington
- Seattle Cancer Care Alliance - Seattle
- Seattle Cancer Care Alliance - Seattle
- University of Washington Medical Center - Seattle
Connecticut
- Smilow Cancer Hospital at Yale New Haven - New Haven
- Smilow Cancer Hospital at Yale-New Haven - New Haven
Minnesota
- University of Minnesota Medical Center - Minneapolis
- University of Minnesota - Minneapolis
Virginia
- Inova Schar Cancer Institute Infusion Pharmacy - Fairfax
- Inova Schar Cancer Institute - Fairfax
Massachusetts
- Massachusetts General Hospital - Boston
Buenos Aires
- Centro de Investigacion Pergamino S.A. - Pergamino
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2016-04-25 |
| Est. Completion | 2023-03-28 |
| Phase | Phase 3 |
What the finished NCT02603432 record still lists
NCT02603432 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 546-participant average among 25 other Urothelial Cancer trials with a reported enrollment target (28% higher).
The record links to 1 condition, with Urothelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Avelumab is the first listed.
NCT02603432 names 20 study sites across 8 states, led by Colorado, Ohio, Washington.
Frequently Asked Questions
What is clinical trial NCT02603432 about?
NCT02603432 is a clinical study titled "A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)". The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of ...
What is the current status of trial NCT02603432?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2016-04-25. Estimated completion is 2023-03-28.
What conditions does trial NCT02603432 study?
This clinical trial studies the following conditions: Urothelial Cancer.
What interventions are being tested in trial NCT02603432?
The interventions under investigation include: Avelumab (BIOLOGICAL), Best Supportive Care (OTHER), Following the planned interim analysis for this study: Avelumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02603432?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02603432 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02603432's enrollment target sits among peer trials
700 6th of 25 higher than 20 of 25 other Urothelial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urothelial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
ACTIVE NOT RECRUITING · Phase 3
-
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI